In 2009, the BC study by Peterson and colleagues evaluated the contribution of TIMP-2 genotypes to BC risk using 19 TIMP-2 polymorphic sites in a population consisting of 1062 BC cases and 1069 healthy controls. This evidence concerns the gene TIMP2 and breast cancer.